



**SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD.**  
Regd. Office: Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur-302015(Raj.)  
Phone: 0141-2742557, 2742266 CIN: L85110RJ1989PLC005206  
E-Mail: sharmaeastindia@gmail.com Website: [www.jaipurhospital.co.in](http://www.jaipurhospital.co.in)

**10.02.2024**  
**At Jaipur**

To,  
The Manager,  
Corporate Relationship Department,  
BSE Ltd.  
25th Floor P.J. Towers,  
Dalal Street, Fort,  
MUMBAI-400 001.

**Ref: Scrip Code: - 524548 - Sharma East India Hospitals and Medical Research Ltd.**

**Sub: Outcome of Board Meeting held on Saturday 10.02.2024 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

Dear Sir/Ma'am,

We wish to inform you that the Board of Directors of the Company at their 06/2023-24 meeting held on Saturday 10<sup>th</sup> February 2024 at the registered office of the Company situated at Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur-302015, Rajasthan which commenced at 04:00 P.M. to 5.15 p.m. inter alia transacted the following business:-

1. Approved the Un-audited Financial Results of the Company for the quarter and Nine Months ended on 31<sup>st</sup> December, 2023 in compliance with Regulation 33 of the Listing Regulations. (Signed copy of the Un-audited Financial Results is enclosed herewith). Further, the extract of Financial Results would also be published in the newspapers in compliance with Regulation 47 of the Listing Regulations.
2. Took on record the Limited Review Report on the Un-audited Financial Results for the quarter and Nine Months ended on 31<sup>st</sup> December, 2023 (Copy enclosed).

Kindly take it on record and acknowledge the same.

Thanking You,

Yours faithfully

For **SHARMA EAST INDIA HOSPITALS &  
MEDICAL RESEARCH LIMITED**

  
**Bhawana Sharma**  
(Company Secretary  
And Compliance Officer)  
M.No. A61665





**Independent Auditor's Limited Review Report on Un-audited Quarterly Financial Results for the Quarter ended 31.12.2023 and Year to Date Financial Results for the period from 01.04.2023 to 31.12.2023 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended)**

To,  
The Board of Directors  
Sharma East India Hospitals & Medical Research Ltd

1. We have reviewed the accompanying Statement of Un-audited Financial Results of Sharma East India Hospitals & Medical Research Limited (the "Company") for the Quarter ended 31.12.2023 and Year to date results for the Quarter and Nine Months ended on December 31<sup>st</sup>, 2023 (for the period April 01<sup>st</sup>, 2023 to December 31<sup>st</sup>, 2023), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended), including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with

the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR GOPAL SHARMA & CO.  
CHARTERED ACCOUNTANTS**



**(CA GAUTAM SHARMA)  
PARTNER**

**Membership No. 079225  
Firm Registration No. 002803C  
UDIN: 24079225BKEQVA1436**



**Jaipur  
February 10, 2024**

---



**SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED**  
NEAR SMS STADIUM, LAL KOTHI, TONK ROAD  
JAIPUR

CIN: L85110RJ1989PLC005206

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2023**

(Rs. In lakhs, Except per share Data)

S. No.	Particulars	Quarter Ended			Year to date Ended		Year Ended
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
<b>1</b>	<b>Income from Operations</b>						
(a)	Revenue from Operations	584.90	536.34	543.66	1,672.23	1,563.84	2,072.58
(b)	Other Income	-	-	1.22	-	1.22	6.40
	<b>Total Revenue</b>	<b>584.90</b>	<b>536.34</b>	<b>544.88</b>	<b>1,672.23</b>	<b>1,565.06</b>	<b>2,078.98</b>
<b>2</b>	<b>Expenses</b>						
(a)	Cost of materials consumed	91.12	88.74	116.00	286.19	320.86	412.15
(b)	Purchase of stock in trade	32.09	19.90	18.31	73.16	33.82	51.51
(c)	Change in Inventories of stock in trade	0.00	-	-	-	-	(6.15)
(d)	Employee benefits expense	62.45	62.21	44.25	180.12	152.48	212.63
(e)	Finance cost	30.60	22.14	32.73	80.67	85.30	118.12
(f)	Depreciation and amortisation expense	35.05	33.89	38.85	102.49	96.43	139.02
(g)	Share of consultants	122.25	78.85	-	290.07	-	316.05
(h)	Accommodation and Surgery Expenses	124.95	129.41	-	398.53	-	527.77
(i)	Other Expenses	62.91	82.99	271.98	198.71	818.53	228.60
	<b>Total Expenses</b>	<b>561.42</b>	<b>518.13</b>	<b>522.12</b>	<b>1,609.94</b>	<b>1,507.42</b>	<b>1,999.70</b>
<b>3</b>	<b>Profit/(Loss) before exceptional items &amp; tax (1-2)</b>	<b>23.48</b>	<b>18.21</b>	<b>22.56</b>	<b>62.29</b>	<b>57.64</b>	<b>79.28</b>
<b>4</b>	<b>Exceptional Items</b>	-	-	-	-	-	-
<b>5</b>	<b>Profit/(Loss) before tax (3-4)</b>	<b>23.48</b>	<b>18.21</b>	<b>22.56</b>	<b>62.29</b>	<b>57.64</b>	<b>79.28</b>
<b>6</b>	<b>Tax expense</b>						
	Current tax / MAT	-	(7.21)	6.27	-	17.07	-
	Taxation for Earlier years	-	-	-	-	-	-
	Deferred tax	-	(3.54)	(5.74)	-	(5.42)	(4.12)
	<b>Total Tax Expenses</b>	<b>-</b>	<b>(10.75)</b>	<b>2.53</b>	<b>-</b>	<b>11.65</b>	<b>(4.12)</b>
<b>7</b>	<b>Profit/(Loss) for the period (5-6)</b>	<b>23.48</b>	<b>28.96</b>	<b>20.03</b>	<b>62.29</b>	<b>45.99</b>	<b>83.40</b>
<b>8</b>	<b>Other Comprehensive Income</b>						
	Changes in fair value of investments in equity shares carried at fair value through OCI	-	-	-	-	-	15.54
(i)	Items that will not be reclassified to profit or loss	-	-	-	-	-	(1.61)
(ii)	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	13.93
	<b>Other Comprehensive Income for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>13.93</b>
<b>9</b>	<b>Total Comprehensive Income (7+8)</b>	<b>23.48</b>	<b>28.96</b>	<b>20.03</b>	<b>62.29</b>	<b>45.99</b>	<b>97.33</b>
<b>10</b>	<b>Paid up equity share capital (face value of Rs. 10/- each)</b>	<b>328.38</b>	<b>328.38</b>	<b>328.38</b>	<b>328.38</b>	<b>328.38</b>	<b>328.38</b>
<b>11</b>	<b>Earnings per share</b>						
	Basic	0.72	0.88	0.61	1.90	1.40	2.96
	Diluted	0.72	0.88	0.61	1.90	1.40	2.96

For SHARMA EAST INDIA HOSPITALS  
AND MEDICAL RESEARCH LIMITED

Sh.   
Authorised Signatory



**Notes:-**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 10<sup>th</sup> February, 2024. The statutory Auditors have carried out Limited Review of above Financial Results.
2. The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBIHO/DDHS/CIR/P/2018/144 Dated "26 November, 2018."
3. The figures of the previous period / year have been re-grouped /re-arranged and / or recast wherever found necessary.
4. These results have been prepared in accordance with Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended), including relevant circulars issued by the SEBI from time to time.

**For SHARMA EAST INDIA HOSPITALS &  
MEDICAL RESEARCH LIMITED**

**For SHARMA EAST INDIA HOSPITALS  
AND MEDICAL RESEARCH LIMITED**

  
**Shailendra Kumar Singh**  
**(Managing Director)**  
**DIN 00432070**



**10.02.2024**  
**At Jaipur**